H. Preisler

发表

Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx.

W. Panje, J. Werner, C. Kuropkat, 2002, Auris, nasus, larynx.

Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment.

H. Preisler, V. Gopal, 1994, Leukemia research.

Comparison ofin vitro assays for detecting subpopulations of P388 leukemic cells resistant to AraC

H. Preisler, A. Raza, A. Raza, 1984, Medical oncology and tumor pharmacotherapy.

A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer.

H. Preisler, R. Oldham, W. Reid, 1998, Cancer biotherapy & radiopharmaceuticals.

Hemoglobin synthesis in murine virus‐induced leukemic cells in vitro. III. Effects of 5‐bromo‐2′‐deoxyuridine, dimethylformamide and dimethylsulfoxide

H. Preisler, W. Scher, C. Friend, 1973, Journal of cellular physiology.

Predictors of response of acute nonlymphocytic leukemia.

H. Preisler, A. Raza, 1986, Cancer investigation.

Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study.

R. Larson, G. Browman, H. Preisler, 1989, Blood.

Proto-oncogene transcript levels and acute nonlymphocytic leukemia.

H. Preisler, A. Raza, 1987, Seminars in oncology.

Proto-oncogene expression in HL-60 cells exposed to ara-C.

H. Sato, H. Preisler, 1987, Seminars in oncology.

Differing patterns of proto-oncogene expression in immature and mature myeloid cells.

H. Preisler, A. Kinniburgh, W. Guan, 1987, Leukemia research.

Studies of proto-oncogene expression in the chronic and blastic phases of chronic myelogenous leukemia.

H. Sato, H. Preisler, A. Sandberg, 1990, European journal of cancer.

Proto-oncogene expression in differentiating and non-differentiating chronic myelogenous leukaemia cells.

H. Sato, H. Preisler, Z. Wang, 1990, European journal of cancer.

Differing patterns of human protooncogene expression in peripheral blood and bone marrow acute leukemia cells.

G. Stein, H. Sato, H. Preisler, 1987, Cancer research.

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.

C. Schiffer, H. Preisler, R. Weiss, 1991, Blood.

Studies of the geographic patterns of c‐myc expression in bone marrow

H. Preisler, K. Pavelić, Z. Pavelic, 1991, Cell proliferation.

Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment.

H. Preisler, Y. Rustum, C. Wrzosek, 1982, Medical and pediatric oncology.

Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.

H. Preisler, Y. Rustum, 1979, Cancer research.

Special clinical concerns/problems in the management of MDS and secondary acute myeloid leukemias.

P. Venugopal, H. Preisler, S. Manson, 2001, Cancer treatment and research.

Involvement of bands 9q21-q22 in five cases of acute nonlymphocytic leukemia.

H. Preisler, A. Sandberg, M. Baer, 1989, Cancer genetics and cytogenetics.

Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: A new role for TNF alpha?

P. Venugopal, H. Preisler, H. Preisler, 2000, Microscopy research and technique.

A study of antibiotic therapy in fever of unknown origin in neutropenic cancer patients.

E. Henderson, H. Preisler, S. Björnsson, 1977, Medical and pediatric oncology.

Studies of Components of Patient Protection Programs: Non-absorbable Antibiotics and Low Bacterial Diets

E. Henderson, H. Preisler, I. Goldstein, 1970 .

Gastrointestinal “sterilization” in the treatment of patients with acute leukemia

E. Henderson, H. Preisler, I. Goldstein, 1970, Cancer.

Serologic diagnosis of disseminated candidiasis in patients with acute leukemia.

E. Henderson, H. Preisler, A. A. Levitan, 1968, Annals of internal medicine.

Selection of optimal remission consolidation therapy for individual patients with acute myelogenous leukemia

R. Larson, G. Tricot, H. Preisler, 2000 .

Phenylbutazone-induced myelodysplastic syndrome with Philadelphia translocation.

H. Preisler, A. Raza, A. Sandberg, 1987, Cancer genetics and cytogenetics.

c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma.

H. Preisler, L. Pavelic, Z. Pavelic, 1992, Cancer research.

Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML.

H. Preisler, 2001, Cancer treatment and research.

The Effects of the Farnesyl Transferase Inhibitor FTI L-778,123 on Normal, Myelodysplastic, and Myeloid Leukemia Bone Marrow Progenitor Proliferation In Vitro

H. Preisler, H. Preisler, A. Raza, 2003, Leukemia & lymphoma.

Effectiveness of Interferon-Alfa and Mid-Cycle Chemotherapy Added to an Anthracycline-Based Regimen in the Treatment of Aggressive Non-Hodgkin's Lymphoma

P. Venugopal, H. Preisler, S. Enschede, 2001, Leukemia & lymphoma.

Bone Marrow Toxicity of Antitumor Agents

H. Preisler, J. Kirshner, 1985 .

Predicting remission outcome in acute non-lymphocytic leukemia: general principles and their application to residual marrow leukemia.

G. Browman, H. Preisler, 1992, Leukemia research.

An Integrated Approach to the Study and Treatment of Acute Myelocytic Leukemia

H. Preisler, 1982 .

Tyrosine phosphorylation of Shc proteins in normal CD34+ progenitor cells and leukemic cells.

P. Venugopal, H. Preisler, J. Yang, 1999, Blood.

Polyribosome Profiles and Polyribosome-Associated RNA of Friend Leukaemia Cells Following DMSO-induced Differentiation

H. Preisler, W. Scher, C. Friend, 1973 .

Proto-oncogene expression during early myeloid differentiation of normal peripheral blood progenitor cells.

H. Sato, H. Preisler, Hiroshi Sato, 1989, Leukemia research.

Enhanced expression of the granulocyte-macrophage colony stimulating factor gene in acute myelocytic leukemia cells following in vitro blast cell enrichment.

H. Preisler, M. Baer, Z. Wang, 1988, Blood.

Transposition of breakpoint cluster region (3' bcr) in CML cells with variant Philadelphia translocations.

H. Preisler, A. Raza, A. Sandberg, 1987, Cancer genetics and cytogenetics.

Breakpoint cluster region rearrangements in chronic myelogenous leukemia with a masked Philadelphia chromosome.

H. Preisler, A. Raza, A. Sandberg, 1987, Cancer genetics and cytogenetics.

Double labeling and in vitro versus in vivo incorporation of bromodeoxyuridine in patients with acute nonlymphocytic leukemia.

H. Preisler, K. Ucar, A. Raza, 1985, Cytometry.

Double labeling of S-phase murine cells with bromodeoxyuridine and a second DNA-specific probe.

H. Preisler, K. Ucar, A. Raza, 1985, Cancer research.

Rapid enumeration of S-phase cells by means of monoclonal antibodies.

H. Preisler, R. Bankert, G. Mayers, 1984, The New England journal of medicine.

Acute myelogenous leukemia subsequent to therapy for a different neoplasm: Clinical features and response to therapy

G. Lyman, H. Preisler, 1977, American journal of hematology.

Studies on the control of differentiation of murine virus-induced erythroleukemic cells.

H. Preisler, W. Scher, C. Friend, 1974, Current topics in developmental biology.

The effects of 13-cis retinoic acid and interferon-alpha in chronic myelogenous leukemia cells in vivo in patients.

H. Handa, H. Preisler, U. Hegde, 1997, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

A hypothesis regarding the development of acute myeloid leukemia from preleukemic disorders. The role of protooncogenes.

H. Preisler, 1988, Cancer genetics and cytogenetics.

Treatment of Refractory Adult Acute Lymphocytic Leukaemia and Acute Undifferentiated Leukaemia with an Anthracycline Antibiotic and Cytosine Arabinoside

H. Preisler, A. Gottlieb, A. Early, 1981, British journal of haematology.

Two in situ labeling techniques reveal different patterns of DNA fragmentation during spontaneous apoptosis in vivo and induced apoptosis in vitro.

H. Preisler, A. Raza, S. Gregory, 1995, Anticancer research.

High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study

R. Larson, R. Priore, G. Browman, 1986, American journal of hematology.

Mutation of p53 in Squamous Cell Cancer of the Head and Neck: Relationship to Tumor Cell Proliferation

S. Leurgans, S. Leurgans, W. Panje, 1997, The Laryngoscope.

A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography

H. Preisler, T. Gessner, W. Bolanowska, 2004, Cancer Chemotherapy and Pharmacology.

Detection of K-ras mutation in a patient with multiple tumors.

H. Preisler, P. Kadam, P. Steele, 1996, Cancer genetics and cytogenetics.

CD34 antigen expression of acute myeloid leukemia‐colony forming cells

M. Baccarani, H. Preisler, V. Gopal, 1992 .

Preparation of Autologous Leukemia and Lymphoma Vaccines Expressing α-Gal Epitopes

H. Preisler, U. Galili, J. Plumas, 2001 .

Cytokine gene activity in AML cells in vivo in patients.

P. Venugopal, H. Preisler, S. Bi, 1998, Leukemia research.

Telomerase Activity In Preleukemia And Acute Myelogenous Leukemia

H. Preisler, Jie Yang, A. Raza, 2000, Leukemia & lymphoma.

Growth of human acute myeloblastic leukemic (AML) cells in vitro

H. Preisler, C. Epstein, G. Christoff, 1979, Blut.

Differentiation of myeloid cells in liquid culture. 1. Progenitor cells found in normal perpheral blood

H. Preisler, E. Archimbaud, 1986, Cell biochemistry and function.

Macrophage differentiation of human precursor B-cell line by phorbol ester and colony-stimulating factor.

H. Preisler, J. Minowada, K. Kubota, 1982, Blood.

Blindness in a patient with malignant histiocytosis

E. Henderson, H. Preisler, M. Barcos, 1977, Cancer.

Clones of Friend leukemia cells: differences in karyotypes and responsiveness to inducers of differentiation.

H. Preisler, A. Sandberg, M. Mori, 1976, Cell differentiation.

Granulocyte differentiation by Friend leukemia cells.

H. Preisler, M. Barcos, M. Mori, 1975, Cell differentiation.

A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH.

P. Venugopal, I. Janssen, H. Preisler, 2003, Leukemia research.

Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B.

K. Rai, H. Preisler, J. Yates, 1987, Haematology and blood transfusion.

Failure of remission induction in acute myelocytic leukemia.

H. Preisler, 1978, Medical and pediatric oncology.

The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows.

P. Venugopal, H. Handa, H. Preisler, 1999, International journal of hematology.

The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines.

H. Preisler, A. Raza, S. Gregory, 1996, Leukemia research.

The selective use of AMSA following high‐dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study

R. Day, R. Larson, J. Bennett, 1992, British journal of haematology.

OPEN FORUM A paradigm shift in myelodysplastic syndromes

P. Venugopal, H. Preisler, Stan Rifkin, 2019 .

Pilot Study of Pentoxifylline and Ciprofloxacin with or without Dexamenthasone Produces Encouraging Results in Myelodysplastic Syndromes

P. Venugopal, H. Preisler, A. Raza, 1998 .

A paradigm shift in myelodysplastic syndromes.

P. Venugopal, H. Preisler, A. Raza, 1996, Leukemia.

CD34+ Cell Selection: Focus on Immunomagnetic Beads and Chymopapain

M. Baccarani, H. Preisler, H. Preisler, 1993, International Journal of Artificial Organs.

Comparison of two methods for concentrating CD34+ cells from patients with acute non-lymphocytic leukemia.

M. Baccarani, H. Preisler, V. Gopal, 1992, Leukemia & lymphoma.

The treatment of the myelodysplastic syndromes

H. Preisler, 1999, Cancer.

Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia [letter]

R. Larson, G. Browman, H. Preisler, 1991 .

Lack of erythroid burst-promoting activity in the media conditioned by eleven human T cell leukemia-lymphoma cell lines.

H. Preisler, J. Minowada, K. Kubota, 1982, Experimental hematology.

Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens.

E. Henderson, H. Preisler, Y. Rustum, 1979, Blood.

The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications.

M. Baccarani, H. Preisler, S. Banavali, 1992, Haematologica.

Friend leukemia cells: relationship between differentiation, clonogenicity and malignancy.

H. Preisler, Y. Rustum, P. Pavelic, 1978, Cell differentiation.

Cytogenetic study of maturing granulocytes in bone marrow of patients with acute myelogenous leukemia.

H. Preisler, A. Sandberg, M. Baer, 1990, Leukemia.

155 Successful anti-cytokine based approach to treat myelodysplastic syndromes (MDS)

H. Preisler, A. Raza, S. Gregory, 1997 .

Cytokines, molecular biological abnormalities, and acute myelogenous leukemia.

P. Venugopal, H. Preisler, S. Bi, 1997, Leukemia research.

Effect of interferon-α on CD20 antigen expression of B-cell chronic lymphocytic leukemia

P. Venugopal, H. Preisler, C. Deshpande, 2000 .

Mitoxantrone and 5‐azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study

J. Bryant, G. Browman, H. Preisler, 1993, American journal of hematology.

Acute myelogenous leukemia with leukemia cutis. Eighteen cases seen between 1969 and 1986

H. Preisler, A. Raza, M. Baer, 1989, Cancer.

Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia.

H. Preisler, A. Raza, Y. Maheshwari, 1987, Blood.

The treatment of acute non-lymphocytic leukemia.

H. Preisler, 1987, Blood reviews.

TREATMENT CHOICES FOR PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA IN REMISSION: CHEMOTHERAPY AND BONE MARROW TRANSPLANTATION

H. Preisler, 1985 .

Uptake of adriamycin by human leukemic cells as measured by flow cytometry

H. Preisler, A. Raza, 1984, Medical oncology and tumor pharmacotherapy.

The effects of exposure to cytosine arabinoside upon the proliferation of leukemia colony forming units in vitro.

H. Preisler, 1982, Medical and pediatric oncology.

Rational approaches to the treatment of leukemia.

H. Preisler, 1981, Haematology and blood transfusion.

Remission induction in acute nonlymphocytic leukemia: comparison of a seven-day and ten-day infusion of cytosine arabinoside in combination with adriamycin.

E. Henderson, H. Preisler, W. Hryniuk, 1979, Medical and pediatric oncology.

Comparison between agar and methylcellulose cultures of human leukemic cells.

H. Preisler, J. Minowada, K. Kubota, 1981, Cancer research.

Clonal Growth of Leukaemic Cells In Vitro

H. Preisler, J. Epstein, 1981, Cell and tissue kinetics.

An acquired Robertsonian translocation dic(14;14)(p11;p11) in a patient with a myelodysplastic syndrome following treatment of multiple myeloma.

H. Preisler, S. Sait, A. Sandberg, 1988, Cancer genetics and cytogenetics.

AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA IN REMISSION

H. Preisler, A. Raza, 1987 .

Prediction of response to chemotherapy in acute myelocytic leukemia.

H. Preisler, 1980, Blood.

Prediction of therapeutic response in acute myelocytic leukemia.

H. Preisler, Y. Rustum, 1979, Haematology and blood transfusion.

Kinetic Resistance, Regrowth Resistance, and Multidrug Resistance in the Treatment of Acute Myelogenous Leukemia (AML)

H. Preisler, A. Raza, 1996 .

Determinants of response and prediction of response to chemotherapy in acute myelogenous leukemia.

H. Preisler, 1991, Bailliere's clinical haematology.

Hemoglobin biosynthesis in murine virus-induced leukemic cells in vitro: structure and amounts of globin chains produced.

H. Preisler, S. Boyer, A. Bank, 1972, Blood.

Neoplastic Progression of the Myeloid Leukemias

H. Preisler, A. Raza, 1989 .

In Vivo Effects of IL-4, IL-10, and Amifostine on Cytokine Production in Patients with Acute Myelogenous Leukemia

P. Venugopal, H. Preisler, Biaoru Li, 2001, Leukemia & lymphoma.

Lack of relationship between in vitro cell measurements and response to busulfan in chronic myelocytic leukemia

H. Preisler, A. Raza, J. Kirshner, 1985, American journal of hematology.

Protooncogene expression in subpopulations of cells from leukemia patients.

H. Preisler, V. Gopal, S. Banavali, 1992, Cytometry.

Poor prognosis acute myelogenous leukemia 2--biological and molecular biological characteristics and treatment outcome.

P. Venugopal, H. Preisler, J. Yang, 2000, Leukemia research.

Translocation (2;7)(p13;q36) in a case of acute nonlymphocytic leukemia evolving from a myelodysplastic syndrome.

F. Solé, H. Preisler, A. Sandberg, 1988, Cancer genetics and cytogenetics.

Phospholipid membrane stabilization by dimethylsulfoxide and other inducers of Friend leukemic cell differentiation.

G. Lyman, H. Preisler, D. Papahadjopoulos, 1976, Biochimica et biophysica acta.

Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation

G. Lyman, H. Preisler, D. Papahadjopoulos, 1976, Nature.

Alteration of binding of the supravital dye Hoechst 33342 to human leukemic cells by adriamycin.

H. Preisler, 1978, Cancer treatment reports.

Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C.

H. Preisler, Y. Rustum, C. Riva, 1987, Seminars in oncology.

Improved rapid autoradiography with elimination of background

H. Preisler, A. Raza, C. Spiridonidis, 1985, Cell biochemistry and function.

Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1

P. Venugopal, H. Preisler, A. Raza, 2000, British journal of haematology.

Poor prognosis acute myelogenous leukemia.

H. Preisler, 1993, Leukemia & lymphoma.

Point mutations in both transforming and non-transforming codons of the N-ras proto-oncogene of Ph+ leukemias.

H. Preisler, G. Rovera, O. Tournay, 1989, Oncogene.

Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside

R. Larson, R. Priore, K. Rai, 1984, British journal of haematology.

Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents.

H. Preisler, V. Gopal, S. Banavali, 1992, Cancer research.

Separation of leukemic myeloblasts and splenic lymphocytes based upon differences in light scatter profile.

H. Preisler, G. Hausner, 1979, Life sciences.

Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements

G. Tricot, R. Priore, K. Rai, 1986, British journal of haematology.

Different Sensitivities of Granulocyte‐Macrophage and Erythroid Progenitor Cells of Normal Human Bone Marrow to S‐Phase‐Specific Agents

H. Preisler, Kazuo Kubota, Catherine Costanzo, 1984, Cell and tissue kinetics.

In vitro busulfan sensitivity of granulocyte-macrophage and erythroid progenitor cells in patients with chronic myelogenous leukemia.

H. Preisler, Y. Miura, K. Kubota, 1983, Cancer research.

Effects of S-phase-specific agents on granulocyte-macrophage and erythroid progenitor cells obtained from normal individuals and from patients with chronic myelogenous leukemia.

H. Preisler, K. Kubota, C. Costanzo, 1983, Cancer research.

Comparison of tritiated thymidine labeling and suicide indices in acute nonlymphocytic leukemia.

H. Preisler, D. Shoham, 1978, Cancer research.

Expression of hematopoietic progenitor cell associated antigen CD34 in chronic myeloid leukemia.

H. Preisler, C. Civin, A. Srivastava, 1991, Leukemia research.

Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia

R. Larson, G. Browman, H. Preisler, 1993, American journal of hematology.

Evaluation of in vitro predictive assays for acute myelocytic leukemia

H. Preisler, 1980, Blut.

Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukaemia.

H. Preisler, A. Raza, S. Banavali, 1994, European journal of cancer.

In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia.

H. Preisler, A. Raza, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

BUDR inhibition of post-DMSO-induced erythroleukaemia cell differentiation in vitro.

H. Preisler, 1976, British Journal of Cancer.

Differentiation of erythroleukemic cells in vitro: Irreversible induction by dimethyl sulfoxide (DMSO)

H. Preisler, M. Giladi, Harvey D. Preisler, 1975, Journal of cellular physiology.

HEMOGLOBIN BIOSYNTHESIS IN MURINE VIRUS‐INDUCED LEUKEMIA CELLS IN VITRO *

H. Preisler, W. Scher, C. Friend, 1974, Annals of the New York Academy of Sciences.

Differentiation of erythroleukemia cells in vitro: properties of chemical inducers.

G. Lyman, H. Preisler, 1975, Cell differentiation.

The Premyelodysplastic State and the Secondary Hematologic Disorders

H. Preisler, S. Bi, Jie Yang, 1998 .

Recent Advances in Hematology: As Related to Diseases of the Colon and Rectum

H. Preisler, J. Cuttner, 1972 .

Immunoperoxidase detection of myeloid antigens in glycolmethacrylate-embedded human bone marrow.

H. Preisler, E. Archimbaud, A. Islam, 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

In vitro drug sensitivity studies of CFUc in chronic myelocytic leukemia: I. Suicide indices and busulfan sensitivity determinations during the chronic phase.

H. Preisler, J. Kirshner, 1983, Experimental hematology.

Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia.

S. Perry, R. Simon, E. Henderson, 1973, The New England journal of medicine.

Anti-Candida antibodies in patients with acute leukemia. A prospective study.

E. Henderson, H. Preisler, H. Hasenclever, 1971, The American journal of medicine.

A prospective study of anti‐candida interfering factor in leukemic patients

E. Henderson, H. Preisler, D. Louria, 1972, Cancer.

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

C. Bloomfield, N. Nissen, K. Rai, 1981, Blood.

Cell kinetics of head and neck cancers.

W. Panje, D. Caldarelli, J. Hutchinson, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis

H. Preisler, A. Raza, S. Shott, 1995, American journal of hematology.

Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients.

R. Larson, H. Preisler, V. Gopal, 1993, Leukemia & lymphoma.

Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia

R. Larson, G. Browman, H. Preisler, 1993, American journal of hematology.

Cell Cycle Parameters as Biological Predictors of Prognosis in AML: A Review and Update of Cell Cycle Kinetics and Remission Induction/Duration in Acute Leukemia

H. Preisler, A. Raza, S. Bokhari, 1992 .

Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia

Naveed Yousuf, Richard Larson, R. Larson, 1991, British journal of haematology.

Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study.

R. Day, G. Browman, H. Preisler, 1990, Blood.

A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr.

H. Preisler, A. Raza, N. Mandava, 1987, Leukemia research.

Cryoprotective agents as inducers of erythroleukemic cell differentiation in vitro.

H. Preisler, G. Christoff, E. Taylor, 1976, Blood.

Studies on erythroid differentiation of Friend virus-induced murine leukemic cells.

H. Preisler, W. Scher, C. Friend, 1973, Bibliotheca haematologica.

Effects of Corynebacterium parvum on murine myeloid leukaemia.

H. Preisler, Z. Pavelic, S. Bjornsson, 1978, British Journal of Cancer.

Sustained viability of acute myelogenous leukemia cells in liquid suspension culture correlates with occurrence of differentiation.

H. Preisler, M. Baer, X. Gao, 1988, Leukemia research.

Differentiation of myeloid cells in liquid culture: 2. Acute myelocytic leukemia cells

H. Preisler, E. Archimbaud, 1987, Cell biochemistry and function.

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.

C. Schiffer, H. Preisler, R. Weiss, 1991, Blood.

Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study.

H. Preisler, A. Gottlieb, H. Hoagland, 1987, Blood.

High-dose cytosine arabinoside therapy in acute non-lymphocytic leukemia.

H. Preisler, 1984, European journal of cancer & clinical oncology.

A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.

H. Preisler, Y. Rustum, H. Slocum, 1982, Cancer research.

Effects of cytosine arabinoside on DNA synthesis and mitotic activity of HL-60 cells

H. Preisler, A. Raza, S. C. Zhao, 1985, Medical oncology and tumor pharmacotherapy.

High-dose cytosine arabinoside: clinical response to therapy in acute leukemia.

G. Browman, H. Preisler, D. Higby, 1982, Medical and pediatric oncology.

Effects of cytosine arabinoside on unseparated bone marrow and peripheral blood cells and on specimens enriched for myeloblasts and promyelocytes.

H. Preisler, Y. Rustum, J. Epstein, 1980, Experimental hematology.

Effect of cytosine arabinoside and 1,3-bis(2-chloroethyl)-1-nitrosourea on hematopoietic precursors in the mouse.

E. Henderson, H. Preisler, 1971, Journal of the National Cancer Institute.

The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemia

R. Priore, G. Browman, H. Preisler, 1983, American journal of hematology.

Effects of cytosine arabinoside on DNA synthesis and the clonogenicity of RF/UN murine myeloid leukemia cells.

H. Preisler, J. Epstein, 1980, Experimental hematology.

Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.

H. Preisler, J. Coon, S. Seelig, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Proliferation of epithelia of noninvolved mucosa in patients with head and neck cancer

W. Panje, D. Caldarelli, J. Hutchinson, 1996, Head & neck.

The ABL/BCR fusion gene on chromosome 9 in Ph-negative chronic myelogenous leukemia: a case for vigilance in fluorescence in situ hybridization interpretation.

K. Szego, H. Preisler, X. Gao, 1998, Cancer genetics and cytogenetics.

Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis.

W. Panje, D. Caldarelli, J. Hutchinson, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

The treatment of acute myelocytic leukemia in patients 30 years of age and younger

G. Browman, H. Preisler, A. Raza, 1982, American journal of hematology.

An autopsy study of 1206 acute and chronic leukemias (1958 to 1982)

E. Henderson, H. Preisler, W. Lane, 1987, Cancer.

Reduced production of spleen colonies and granulocytes in antibiotic-treated irradiated mice transplanted with syngeneic bone marrow.

E. Henderson, H. Preisler, H. Bruckner, 1971, Radiation research.

Alcian blue method for attaching glycol methacrylate bone marrow sections to glass slides.

H. Preisler, E. Archimbaud, A. Islam, 1986, Stain technology.

Ph1-positive acute leukemia.

H. Preisler, J. Minowada, M. Barcos, 1984, European journal of cancer & clinical oncology.

Four cases with complex Philadelphia translocations, including one with appearance de novo of a "masked" Ph.

H. Preisler, A. Raza, A. Sandberg, 1987, Cancer genetics and cytogenetics.

Expression of the multidrug resistance gene in myeloid leukemias.

I. Pastan, M. Gottesman, H. Sato, 1990, Leukemia research.

Adriamycin-cytosine arabinoside therapy for adult acute myelocytic leukemia.

E. Henderson, H. Preisler, S. Bjornsson, 1977, Cancer treatment reports.

Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.

R. Priore, H. Preisler, Y. Rustum, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside

R. Priore, H. Preisler, Y. Rustum, 2004, Cancer Chemotherapy and Pharmacology.

Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia

R. Larson, G. Browman, H. Preisler, 2004, Cancer Chemotherapy and Pharmacology.

Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.

R. Larson, G. Browman, H. Preisler, 1993, Leukemia & lymphoma.

The frequency of long‐term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow‐up time of 6 years

K. Rai, H. Preisler, J. Yates, 1989, British journal of haematology.

Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.

R. Priore, H. Preisler, Y. Rustum, 1985, European journal of cancer & clinical oncology.

Assessment of the drug sensitivity of acute nonlymphocytic leukaemia using the in vitro clonogenic assay

H. Preisler, N. Azarnia, 1984, British journal of haematology.

Prevention of infection and bleeding in leukemic patients receiving intensive remission maintenance therapy.

H. Preisler, W. Hryniuk, A. Early, 1981, Medical and pediatric oncology.

Separation of leukemic cells into proliferative and quiescent subpopulations by centrifugal elutriation.

H. Preisler, Y. Rustum, Y M Rustum, 1977, Cancer research.

Regulators of Proliferation and Apoptosis in Carcinoma of the Larynx

S. Leurgans, W. Panje, D. Caldarelli, 1998, The Laryngoscope.

Comparison of autoradiography and DNA histograms in assessing S-phase cells from patients with myeloid leukemias

H. Preisler, A. Raza, K. Kuliczkowski, 1985, Medical oncology and tumor pharmacotherapy.

Treatment of patients with acute nonlymphocytic leukemia in relapse: A leukemia intergroup study

R. Priore, K. Rai, G. Browman, 1985, American journal of hematology.

Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure.

H. Preisler, P. Reese, L. Pothier, 1983 .

Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure

H. Preisler, P. Reese, L. Pothier, 1983, British journal of haematology.

Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: utility of day 6 bone marrow biopsy.

R. Priore, H. Preisler, M. Barcos, 1983, Leukemia research.

Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase.

H. Handa, H. Preisler, U. Hegde, 1997, Leukemia research.

The role of emerging technologies in the diagnosis and staging of neoplastic diseases

H. Preisler, A. Raza, 1992, Cancer.

Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.

W. Panje, D. Caldarelli, J. Hutchinson, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

T-cell depletion of bone marrow does not inhibit in vitro hematopoiesis

H. Preisler, M. O'Leary, H. Ozer, 1985, Blut.

Human T cell leukemia-lymphoma cell lines and granulocyte-macrophage colony stimulating activity.

H. Preisler, J. Minowada, K. Kubota, 1980, Immunological communications.

Clonogenic potential in vitro of proliferative and quiescent leukemic cells.

H. Preisler, 1980, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Isolation and characterization of the CD34+ hematopoietic progenitor cells from the peripheral blood of patients with chronic myeloid leukemia.

H. Preisler, C. Civin, S. Banavali, 1991, International journal of cell cloning.

Effect of suppression of erythropoiesis on hematopoietic stem cells in the mouse

E. Henderson, H. Preisler, 1972, Journal of cellular physiology.

MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia

R. Day, I. Pastan, R. Larson, 1990, British journal of haematology.

Chronic myelocytic leukemia: comments on new approaches to therapy.

H. Preisler, A. Raza, 1982, Cancer treatment reports.

Chromosomes and causation of human cancer and leukemia. LIV. Near-tetraploidy in acute leukemia.

H. Preisler, A. Raza, A. Sandberg, 1985, Cancer genetics and cytogenetics.

Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients.

R. Larson, H. Preisler, A. Raza, 1992, Blood.

Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia.

P. Venugopal, H. Preisler, S. Gregory, 2000, Leukemia research.

Comparison of agar and methylcellulose culture methods for human erythroid colony formation.

H. Preisler, K. Kubota, Preisler Hd, 1982, Experimental hematology.

Marrow cytokine transcripts and the secondary hematologic disorders.

H. Preisler, S. Bi, A. Raza, 1999, Leukemia and Lymphoma.

Erythroid colony formation in vitro by dimethylsulfoxide-treated erythroleukemic cells.

H. Preisler, E. Zanjani, J. Lutton, 1974, Blood.

Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).

H. Preisler, Y. Rustum, C. Riva, 1985, Seminars in oncology.

Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.

K. Rai, G. Browman, H. Preisler, 1986, Cancer treatment reports.

Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.

E. Henderson, H. Preisler, H. Takita, 1978, Cancer treatment reports.

SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients.

P. Venugopal, H. Preisler, R. Huang, 2000, Cytokine.

cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma.

E. Henderson, H. Preisler, C. Karakousis, 1979, Cancer treatment reports.

Effects of prior therapy on plasma levels of adriamycin during subsequent therapy.

H. Preisler, M. Durand, B. Hoerni, 1981, Journal of medicine.

Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia.

M. Baccarani, H. Preisler, A. Raza, 1993, Leukemia & lymphoma.

Cytological and immunological study of 139 patients with acute leukemia

H. Preisler, G. Mathé, J. Minowada, 1984, Medical oncology and tumor pharmacotherapy.

Accuracy of immunohistochemistry and flow cytometry in estimating the proportion of leukemic cells in S phase in chronic myeloid leukemia patients.

H. Handa, H. Preisler, U. Hegde, 1996, Leukemia & lymphoma.

Studies of the proliferation and differentiation of immature myeloid cells in vitro. II. Acute myelogenous leukemia

H. Preisler, Xue-Zhi Gao, Zi-Lin Wang, 1989, American journal of hematology.

Cell cycle studies in acute myelogenous leukemia.

H. Preisler, A. Raza, 1992, Leukemia.

Current problems in the treatment of acute myelocytic leukemia (AML) and some possible solutions.

H. Preisler, A. Raza, 1992, Leukemia.

Effects of rGM‐CSF on leukemia cell proliferation and on the incorporation of cytosine arabinoside into DNA

H. Preisler, A. Raza, M. Yin, 1991, Cell biochemistry and function.

Treatment of myeloid blastic crisis of chronic myelogenous leukemia.

H. Preisler, A. Raza, R. Weiner, 1984, Cancer treatment reports.

Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia

R. Larson, G. Browman, H. Preisler, 2004, Cancer Chemotherapy and Pharmacology.

In vitro drug sensitivity studies of colony-forming units in culture in chronic myelocytic leukemia: lack of specificity between chronic-phase patients and normal donors.

H. Preisler, J. Kirshner, 1983, Cancer research.

Assessment of cell-cycle effects of cytokines in vivo.

H. Preisler, A. Raza, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study

R. Larson, R. Priore, G. Browman, 1989, British journal of haematology.

The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure

R. Day, R. Larson, G. Browman, 1991, British journal of haematology.

Assessment of c-myc expression in individual leukemic cells.

H. Sato, H. Preisler, P. Yang, 1988, Leukemia research.

A proposal regarding the reporting of post-remission induction therapies in acute nonlymphocytic leukemia

H. Preisler, 1986, Medical oncology and tumor pharmacotherapy.

Treatment of dysmyelopoietic/leukemic syndromes with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside

H. Preisler, A. Raza, M. Barcos, 1985, Medical oncology and tumor pharmacotherapy.

Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody

R. Larson, J. Bennett, G. Browman, 1991 .

Cytolytic activity of peripheral blood blast cells from patients with acute myeloid leukemia.

H. Preisler, D. Braun, 1997, Leukemia & lymphoma.

Control of Leukemia Proliferation in vivo in Patients: In vivo Cytokine Production

P. Venugopal, H. Preisler, S. Bi, 1998 .

Prognosis in Head and Neck Cancer

S. Leurgans, W. Panje, D. Caldarelli, 2016 .

Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer.

S. Leurgans, W. Panje, D. Caldarelli, 1998, Archives of otolaryngology--head & neck surgery.

The study of acute leukemia cells by means of acridine orange staining and flow cytometry.

H. Preisler, V. Gopal, A. Raza, 1994, Leukemia & lymphoma.

c-myc detection in bone marrow biopsies.

H. Preisler, K. Pavelić, Z. Pavelic, 1991, Leukemia research.

Cyclin Dl Expression in Squamous Cell Carcinomas of the Head and Neck and in Oral Mucosa in Relation to Proliferation and Apoptosis 1

W. Panje, D. Caldarelli, J. Hutchinson, 2005 .

Evaluation of c-myc proto-oncogene in primary human breast carcinomas.

H. Preisler, Z. Pavelic, P. Steele, 1991, Anticancer research.

A non-clonogenic assay for the determination of the sensitivity of leukemic cells to chemotherapeutic agents.

H. Preisler, J. Epstein, 1983, European Journal of Cancer and Clinical Oncology.

Effects of cytosine arabinoside on DNA synthesis as predictor for acute myelocytic leukemia (AML) patients' response to chemotherapy.

H. Preisler, J. Epstein, 1981, European journal of cancer.

A Comparison of Two Methods for Determining the Sensitivity of Human Myeloid Colony‐forming Units to Cytosine Arabinoside

H. Preisler, J. Epstein, Harvey D. Preisler, 1981, British journal of haematology.

Differences between labeling index and DNA histograms in assessing S-phase cells from a homogeneous group of chronic phase CML patients.

H. Preisler, K. Ucar, R. Bhayana, 1985, Cytometry.

Effects of an IL-1 receptor antagonist on acute myeloid leukemia cells.

H. Preisler, V. Gopal, P. Gartside, 1992, Leukemia.

Acute nonlymphocytic leukemia in a glue sniffer

M. Caligiuri, H. Preisler, A. Early, 1985, American journal of hematology.

A permanent method of detecting SCE by immunofluorescence using monoclonal anti-BrdU antibodies.

H. Preisler, A. Raza, A. Block, 1985, Cancer genetics and cytogenetics.

An overview of some studies of chronic myelogenous leukemia: biological-clinical observations and viewing the disease as a chaotic system.

H. Preisler, A. Raza, 1993, Leukemia & lymphoma.

Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemia intergroup report.

G. Browman, H. Preisler, I. Walker, 1985, Cancer treatment reports.

Another look at survival curves in chronic myelocytic leukemia

H. Preisler, P. A. Reese, 1980, American journal of hematology/oncology.

Erythropoietin-induced stimulation of heme synthesis by dimethylsulfoxide-treated Friend leukemic cells in vitro.

H. Preisler, E. Zanjani, 1974, The Journal of laboratory and clinical medicine.

Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia.

P. Venugopal, H. Preisler, C. Deshpande, 2000, Cytokines, cellular & molecular therapy.

Relationship of the growth of leukemic cells in vitro to the outcome of therapy for acute nonlymphocytic leukemia.

H. Preisler, N. Azarnia, M. Marinello, 1984, Cancer research.

Enzymatic programming of apoptotic cell death.

H. Preisler, S. Gregory, S. Mundle, 1996, Pathobiology : journal of immunopathology, molecular and cellular biology.

Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.

H. Preisler, A. Raza, R. Borok, 1995, Blood.

Alterations in IRF1/IRF2 expression in acute myelogenous leukemia

P. Venugopal, H. Preisler, N. Tanaka, 2001, American journal of hematology.

Drug Uptake and Ribonucleotide Profiles of Blast‐enriched and Blast‐depleted Human Bone Marrow Cell Populations

H. Preisler, Y. Rustum, H. D. Preisler, 1977, British journal of haematology.

The leukemias.

H. Preisler, 1994, Disease-a-month : DM.

Clonogenic potential of myeloid leukaemia cells in vitro is restricted to leukaemia cells expressing the CD34 antigen.

H. Preisler, V. Gopal, R. Kuvelkar, 1993, European journal of cancer.

Autologous bone marrow transplantation for acute leukemia in remission.

H. Preisler, A. Raza, 1987, British journal of haematology.

Effects of partially thiolated polycytidylic acid on the clonogenicity of murine leukemic stem cells.

H. Preisler, Y. Ho, T. Bardos, 1979, Cancer research.

Immunohistochemical detection of c-myc oncoprotein in paraffin embedded tissues.

H. Preisler, K. Pavelić, Z. Pavelic, 1990, Journal of experimental pathology.

Treatment of erythroleukemia with anthracycline antibiotics and cytosine arabinoside

H. Preisler, K. Tamura, Harvey D. Preisler, 1983, Cancer.

Utility and sensitivity of anti BrdU antibodies in assessing S‐phase cells compared to autoradiography

H. Preisler, A. Raza, K. Ucar, 1985, Cell biochemistry and function.

Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy

H. Preisler, N. Azarnia, H. Grunwald, 1987, Medical oncology and tumor pharmacotherapy.

Analysis of cell cycle characteristics and course of the disease in ANLL

H. Preisler, A. Raza, Y. Maheshwari, 1987, American journal of hematology.

Protected environment units in the treatment of acute leukemia.

H. Preisler, S. Bjornsson, 1975, Seminars in oncology.

Carcinoma of unknown primary: natural history and response to therapy.

G. Lyman, H. Preisler, 1978, Journal of medicine.

P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients

P. Venugopal, H. Preisler, H. Preisler, 2001, Leukemia.

Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues.

H. Preisler, J. Coon, L. Cass, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.